<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173547</url>
  </required_header>
  <id_info>
    <org_study_id>146-9251-201</org_study_id>
    <nct_id>NCT03173547</nct_id>
  </id_info>
  <brief_title>A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of 146-9251 Cream Applied Twice-daily for Six Weeks in Subjects With Ichthyosis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crown Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crown Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine and compare the safety and efficacy of topical&#xD;
      146-9251 cream and vehicle cream applied twice daily for 6 weeks in subjects with moderate to&#xD;
      severe ichthyosis vulgaris (IV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>Day 43 (6 weeks)</time_frame>
    <description>Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Day 0 through study completion, average 6 weeks, Day 43.</time_frame>
    <description>AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Ichthyosis Vulgaris</condition>
  <arm_group>
    <arm_group_label>146-9251 cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>146-9251 cream</intervention_name>
    <description>146-9251 cream contains an active drug and is applied topically.</description>
    <arm_group_label>146-9251 cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <description>Vehicle cream does not contain an active drug and is applied topically.</description>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a male or female and is at least 12 years old at the time of enrollment.&#xD;
&#xD;
          2. Subject has provided written informed consent/assent. A subject under 18 years of age&#xD;
             must provide written informed assent and be accompanied by the parent or legal&#xD;
             guardian at the time of assent/consent signing. The parent or legal guardian must&#xD;
             provide informed consent for the subject. If a subject becomes 18 years of age during&#xD;
             the study, the subject must provide written informed consent at that time to continue&#xD;
             study participation.&#xD;
&#xD;
          3. Subject and parent/guardian (if applicable) are willing and able to apply the test&#xD;
             article(s) as directed, comply with study instructions, and commit to all follow-up&#xD;
             visits for the duration of the study.&#xD;
&#xD;
          4. Subject has a clinical diagnosis of ichthyosis vulgaris involving a minimum of 5% body&#xD;
             surface area (BSA). If the subject has IV involving over 40% BSA, the investigator&#xD;
             must be able to identify a Treatment Area comprising distinct anatomic units that&#xD;
             contains about 40% (excluding the scalp and mucosal areas) as detailed in Section 6.2.&#xD;
&#xD;
          5. Subject has an Investigator's Global Assessment (IGA) score of at least three (3 =&#xD;
             moderate) at the Baseline Visit.&#xD;
&#xD;
          6. Subject is in good general health and free of any disease state or physical condition&#xD;
             that might impair evaluation of IV or which, in the investigator's opinion, exposes&#xD;
             the subject to an unacceptable risk by study participation.&#xD;
&#xD;
          7. Females must be post-menopausal, surgically sterile, or use an effective method of&#xD;
             birth control. , Women of childbearing potential (WOCBP) must have with a negative&#xD;
             urine pregnancy test (UPT) at the Baseline Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.&#xD;
&#xD;
             2. Subject is currently enrolled in an investigational drug or device study. 3.&#xD;
             Subject has used an investigational drug or investigational device treatment within 30&#xD;
             days prior to first application of the test article.&#xD;
&#xD;
             4. Subject has used any topical therapy, including topical corticosteroids or&#xD;
             retinoids, in the Treatment Area within 2 weeks prior to the initiation of treatment.&#xD;
             Note: a bland emollient may be used in the Treatment Area up to 3 days prior to the&#xD;
             initiation of treatment.&#xD;
&#xD;
             5. Subject has used systemic corticosteroids within 4 weeks or retinoids within 24&#xD;
             weeks prior to the initiation of treatment.&#xD;
&#xD;
             6. Subject has stable use of vitamin or herbal supplements for less than 2 weeks prior&#xD;
             to the initiation of treatment.&#xD;
&#xD;
             7. Subject has a history of sensitivity to any of the ingredients in the test&#xD;
             articles.&#xD;
&#xD;
             8. Subject is known to be noncompliant or is unlikely to comply with the requirements&#xD;
             of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
             9. Subject has a physical condition or other dermatologic disorders (e.g., atopic,&#xD;
             seborrheic or contact dermatitis, psoriasis, tinea infections, etc.) which, in the&#xD;
             investigator's opinion, might impair evaluation of IV, or which exposes the subject to&#xD;
             unacceptable risk by study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Crown investigative site 01</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crown Investigative site 07</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crown Investigative site 08</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crown Investigative site 02</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crown Investigative site 04</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crown Investigative Site 05</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crown Investigative site 06</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <results_first_submitted>June 23, 2021</results_first_submitted>
  <results_first_submitted_qc>June 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2021</results_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ichthyosis</mesh_term>
    <mesh_term>Ichthyosis, Lamellar</mesh_term>
    <mesh_term>Ichthyosis Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03173547/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>146-9251 Cream</title>
          <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
146-9251 cream: 146-9251 cream contains an active drug and is applied topically.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Cream</title>
          <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
Vehicle cream: Vehicle cream does not contain an active drug and is applied topically.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat (ITT) population defined as subjects who applied at least one dose of the assigned test article.</population>
      <group_list>
        <group group_id="B1">
          <title>146-9251 Cream</title>
          <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
146-9251 cream: 146-9251 cream contains an active drug and is applied topically.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Cream</title>
          <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
Vehicle cream: Vehicle cream does not contain an active drug and is applied topically.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="19.41"/>
                    <measurement group_id="B2" value="51.4" spread="17.42"/>
                    <measurement group_id="B3" value="53.1" spread="18.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment (IGA) Score</title>
          <description>To be eligible for the study, subject must have IGA score of at least three (3=moderate) at their baseline visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>3-Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4-Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success</title>
        <description>Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).</description>
        <time_frame>Day 43 (6 weeks)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>146-9251 Cream</title>
            <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
146-9251 cream: 146-9251 cream contains an active drug and is applied topically.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
Vehicle cream: Vehicle cream does not contain an active drug and is applied topically.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success</title>
          <description>Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events (AEs)</title>
        <description>AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.</description>
        <time_frame>Day 0 through study completion, average 6 weeks, Day 43.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>146-9251 Cream</title>
            <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
146-9251 cream: 146-9251 cream contains an active drug and is applied topically.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
Vehicle cream: Vehicle cream does not contain an active drug and is applied topically.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs)</title>
          <description>AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of Subjects with any AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of Subjects without an AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from study day 1 to end of study (week 6).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>146-9251 Cream</title>
          <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
146-9251 cream: 146-9251 cream contains an active drug and is applied topically.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Cream</title>
          <description>Topical cream to be applied two times daily to specified treatment areas for 6 weeks.&#xD;
Vehicle cream: Vehicle cream does not contain an active drug and is applied topically.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Therapeutics, Inc.</organization>
      <phone>858-571-1800</phone>
      <email>ClinicalResearch@therapeuticsinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

